Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyWed, 17 Jul 2024 03:14:24 +0200Wed, 22 May 2024 13:25:00 +0200Human medicines European public assessment report (EPAR): Amgevita, adalimumab, Date of authorisation: 21/03/2017, Revision: 12, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/amgevitaHuman medicines European public assessment report (EPAR): Amgevita, adalimumab, Date of authorisation: 21/03/2017, Revision: 12, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/amgevitaWed, 22 May 2024 13:25:00 +0200Human medicineAmgevita : EPAR - Summary for the publichttps://www.ema.europa.eu/system/files/documents/overview/wc500225280_en.pdfAmgevita : EPAR - Summary for the publichttps://www.ema.europa.eu/system/files/documents/overview/wc500225280_en.pdfThu, 06 Apr 2017 02:00:00 +0200Human medicine